Cholestyramine · larger labeled portfolio than Bempedoic Acid/Ezetimibe
SPL labels Cholestyramine + Bempedoic Acid/Ezetimibe as minor; Cholestyramine 31 / Bempedoic Acid/Ezetimibe 3 in that band.
Mechanism on file: Cholestyramine can bind to the other medicine, which prevents your body from absorbing it correctly.
FDA SPL severity: Minor
Bempedoic Acid/Ezetimibe
Full Bempedoic Acid/Ezetimibe label recordACL Inhibitor / Cholesterol Absorption Inhibitor
Cholestyramine + Bempedoic Acid/Ezetimibe · SPL mechanism field
Cholestyramine can bind to the other medicine, which prevents your body from absorbing it correctly.
Minor band excerpt · Cholestyramine with Bempedoic Acid/Ezetimibe
Cholestyramine Clinical Impact: Concomitant use of NEXLIZET and cholestyramine decreases ezetimibe concentration. Intervention: Administer NEXLIZET either at least 2 hours before or at least 4 hours after bile acid sequestrants [see Dosage and Administration (2.2) ] .
Cholestyramine · 34 SPL pairs (broader portfolio than Bempedoic Acid/Ezetimibe)
- Amiodarone minor
- Amlodipine/Valsartan minor
- Bempedoic Acid minor
- Carbidopa/Levodopa minor
Bempedoic Acid/Ezetimibe · 3 minor + 7 total pairs
- Cyclosporine minor
- Ezetimibe minor
- Bempedoic Acid moderate
- Fenofibrate moderate
FDA Drug Labels (SPL) via openFDA. Registry display only. Not medical advice.
Read our methodology - how this data is sourced, computed, and verified.